Biomarker Discovery

An increasing number of drug development projects are incorporating the parallel development of biomarkers. Pronota aims to become the pharmaceutical industry's preferred partner for the development of protein biomarkers at any stage of the drug discovery pipeline to:

• Reduce the overall cost of drug development and increase drug value
• Select and monitor patients for shorter, less-expensive advanced clinical trials
• Predict which individuals will respond to drugs at high rates and who will be less likely to suffer toxic side effects
• Ultimately improve and provide more effective healthcare for all individuals

We offer our MASStermind^® approach to R&D partners to:

• Isolate disease progression markers
• Identify markers measuring therapeutic impact, bridging transition from in vitro system to pre-clinical to clinical setting
• Identify protein markers associated with toxicity issues
• Discriminate drug responders from non-responders

We provide our superior approach to determine the value of protease inhibitor drugs and to guide their discovery and clinical development. We offer:

• In vivo identification of protease substrates and substrate specificities
• Protease (inhibitor or activator) profiling
• Identification of specific protease cleavage sites
• Elucidation of protease - substrate pathways in blood